Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte has obtained a milestone payment worth $25m from Novartis due to the advancement of c-MET Inhibitor INC280 into phase II development.
Subscribe to our email newsletter
Phase II trial being conducted by Novartis will assess INC280 as monotherapy in patients with advanced hepatocellular carcinoma.
Under the terms of the deal signed between the companies, Novartis has exclusive development and commercialization rights to INC280, and few back-up compounds in all indications across the world.
The agreement provides Incyte an option to co-develop and co-detail INC280 in the US.
The oral selective inhibitor of the c-MET receptor tyrosine kinase INC280 established encouraging pharmacologic activity and safety profile in preclinical studies.